公告显示，利润下滑主要原因包括医保次均费用下降挤压医疗机构利润，以及公司逐步退出IOT业务导 致相关利润贡献减少。 北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月4日，华润医疗发布公告称，预计2025年上半年公司拥 有人应占利润同比下降20%—25%；若剔除公告所载有关集团一次性收到燕化IOT协议下以前年度管理 费及供应链损失赔偿款项约2.1亿元和对应的企业所得税后，公司拥有人应占利润相较2024年同期下降 约55%—60%。 ...

Core Viewpoint - China Resources Medical (01515.HK) anticipates a decline in profit attributable to shareholders by approximately 20% to 25% for the six months ending June 30, 2025, compared to the same period in 2024. After excluding a one-time management fee and compensation of approximately RMB 210 million from the YanHua IOT agreement, the profit is expected to decrease by about 55% to 60% compared to 2024 [1] Group 1 - The expected profit decline is primarily due to a decrease in average medical expenses under the medical insurance system, leading to reduced operating profits for member medical institutions [1] - The company is gradually exiting the Investment-Operation-Transfer (IOT) business model, resulting in a corresponding decline in profit contribution [1] - In the second half of 2025, the company plans to actively improve its revenue structure, enhance management precision, control operating costs, and increase operational efficiency [1]

公告称，预期利润下降主要由于医保次均费用下降导致成员医疗机构经营利润下降。同时公司逐渐退出 IOT(即投资-运营-移交模式)业务，其对应的利润贡献下降。2025年下半年公司将继续积极改善收入结 构，推动管理精细化，控制运营成本，提高经营效益。 消息面上，8月4日，华润医疗发布公告，公司预料截至2025年6月30日止六个月的公司拥有人应占利润 相较2024年同期下降约20%至25%；而经剔除有关集团一次性收到燕化IOT协议下以前年度管理费及供 应链损失赔偿款项约人民币2.1亿元和对应的企业所得税后，公司拥有人应占利润相较 2024年同期下降 约55%至60%。 智通财经获悉，华润医疗(01515)盈警后低开7%，截至发稿，跌7%，报4.12港元，成交额415.91万港 元。 本文源自智通财经网 ...

港股医药股震荡走低，华润医疗跌超13%，石药集团、复星医药、微创医疗、药明康德、药明生物等跟 跌。 ...

8月4日，华润医疗(01515)盘中下跌8.35%，截至09:30，报4.06元/股，成交1651.07万元。 本文源自：金融界 作者：行情君 华润医疗控股有限公司是内地和香港两地规模领先的医疗上市公司，致力于专业化整合和资本化运作医 疗资源，其经营的医疗机构多达146家，运营床位数超过21985张。公司在2023年收购了母公司华润健康 的36家优质医疗机构，增强了医疗服务能力，并对集团化运营和精细化管理模式进行创新改良，以满足 人民群众的多样化医疗健康服务需求。 截至2024年年报，华润医疗营业总收入98.55亿元、净利润5.66亿元。 ...

公告称，预期利润下降主要由于医保次均费用下降导致成员医疗机构经营利润下降。同时公司逐渐退出 IOT(即投资-运营-移交模式)业务，其对应的利润贡献下降。2025年下半年公司将继续积极改善收入结 构，推动管理精细化，控制运营成本，提高经营效益。 智通财经APP获悉，华润医疗(01515)盈警后低开7%，截至发稿，跌7%，报4.12港元，成交额415.91万 港元。 消息面上，8月4日，华润医疗发布公告，公司预料截至2025年6月30日止六个月的公司拥有人应占利润 相较2024年同期下降约20%至25%；而经剔除有关集团一次性收到燕化IOT协议下以前年度管理费及供 应链损失赔偿款项约人民币2.1亿元和对应的企业所得税后，公司拥有人应占利润相较 2024年同期下降 约55%至60%。 ...

Core Viewpoint - China Resources Medical (01515) issued a profit warning, anticipating a profit decline of approximately 20% to 25% for the six months ending June 30, 2025, compared to the same period in 2024, with a more significant decline of about 55% to 60% when excluding one-time management fees and compensation related to the Yanhua IOT agreement [1][1][1] Group 1 - The company's stock opened lower by 7% and is currently trading at HKD 4.12, with a trading volume of HKD 4.1591 million [1][1] - The anticipated profit decline is primarily attributed to a decrease in average medical expenses under the medical insurance system, leading to reduced operating profits for member medical institutions [1][1][1] - The company is gradually exiting the IOT (Investment-Operation-Transfer) business, resulting in a decline in profit contributions from this segment [1][1][1] Group 2 - For the second half of 2025, the company plans to actively improve its revenue structure, enhance management precision, control operational costs, and increase operational efficiency [1][1][1]

Core Viewpoint - China Resources Medical expects a decline in profit attributable to shareholders by 20% to 25% for the six months ending June 30, 2025, primarily due to reduced average medical expenses under the healthcare insurance system and a gradual exit from the IOT (Investment-Operation-Transfer) business [1] Financial Summary - The profit attributable to shareholders is projected to decline by 55% to 60% when excluding a one-time gain of approximately 210 million RMB from the Yan Hua IOT agreement, which includes management fees and compensation for supply chain losses [1] - The main reason for the profit decline is the decrease in operating profit of its medical institutions due to lower average medical expenses [1] Business Strategy - The company plans to optimize its revenue structure, enhance management efficiency, and control costs in the second half of 2025 to improve operational effectiveness [1]

Core Viewpoint - China Resources Medical (01515) anticipates a decline in profit attributable to shareholders for the six months ending June 30, 2025, by approximately 20% to 25% compared to the same period in 2024, with a more significant drop of about 55% to 60% when excluding one-time management fees and compensation related to the Yanhua IOT agreement totaling approximately RMB 210 million [1] Financial Performance - The expected profit decline is primarily due to a decrease in average medical expenses under the healthcare insurance system, leading to reduced operating profits for member medical institutions [1] - The company is gradually exiting the IOT (Investment-Operation-Transfer) business, resulting in a corresponding decrease in profit contribution from this segment [1] Future Outlook - In the second half of 2025, the company plans to actively improve its revenue structure, promote refined management, control operating costs, and enhance operational efficiency [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 盈利預警 本公告由華潤醫療控股有限公司（「本公司」，連同其子公司統稱為「本集團」）乃根 據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09 (2) (a)條及香港法 例第571章證券及期貨條例第XIVA部的內幕消息條文（ 定義見上市規則 ）作出。 茲提述本公司日期為2025年2月21日的公告（「該公告」），內容有關燕化IOT協議爭 議的最新進展。除文義另有所指外，本公告所用詞彙與該公告所界定者具有相同 涵義。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者， 本公司正在 編製其截至2025年6 月30日止 六個月（「報告期」）之綜合 業績。根據目 前已有資料並對本集團未經審計的報告期綜合管理賬目作出初步評估，本公司預 料報告期的本公 ...